Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Friday, March 31, 2023 1 min read
Key Takeaway: AbbVie Inc. has updated its earnings guidance to include the impact of acquired IPR D and milestones expenses for the first quarter of 2023. The adjusted diluted earnings per share (EPS) range has been revised downward by $0.08 due to these expenses. The company forecasts an adjusted diluted EPS range for Q1 2023 between $2.31 and $2.41, and for the full year, between $10.62 and $11.02, excluding any potential future expenses. There remains uncertainty concerning the predictability of expenses for the rest of 2023.
Market Sentiment Analysis
POSITIVE FACTORS
Guidance reflects a range of adjusted diluted EPS that remains relatively strong.
The company provides detailed expense forecasts for better financial clarity.
CONCERNS & RISKS
Acquired IPR D and milestones expense negatively impacts EPS guidance by $0.08.
Uncertainty regarding future expenses beyond Q1 2023 remains a concern.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended March 31, 2023
Full-Year Ended December 31, 2023
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q1 2023 acquired IPR D and milestones expense
$
-
$
2.39
$
2.49
$
-
$
10.70
$
11.10
Q1 2023 acquired IPR D and milestones expense
150
(0.08)
(0.08)
150
(0.08)
(0.08)
Guidance including Q1 2023 acquired IPR D and milestones expense a
$
150
$
2.31
$
2.41
$
150
$
10.62
$
11.02
a The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the first quarter of 2023, as both cannot be reliably forecasted.
Frequently Asked Questions
What is the acquired IPRD and milestones expense for Q1 2023?
The acquired IPRD and milestones expense for Q1 2023 is $150 million.
What is the adjusted diluted EPS range for Q1 2023?
The adjusted diluted EPS range for Q1 2023 is $2.31 to $2.41.
How did Q1 2023 expense affect full-year EPS guidance?
Including Q1 2023 expenses, full-year EPS guidance is $10.62 to $11.02.
Are future expenses from acquired IPRD predictable?
No, future expenses from acquired IPRD and milestones are not reliably forecasted.
What was the previously announced EPS guidance for 2023?
The previously announced EPS guidance for 2023 was $10.70 to $11.10.